
Koichi Suzuki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4094422/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genomeâ€wide DNA hypomethylation drives a more invasive pancreatic cancer phenotype and has predictive occult distant metastasis and prognosis potential. International Journal of Oncology, 2022, 60, .	3.3	2
2	Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS‑102 plus bevacizumab. Molecular and Clinical Oncology, 2022, 16, 103.	1.0	2
3	Optimal value of CA19-9 determined by KRAS-mutated circulating tumor DNA contributes to the prediction of prognosis in pancreatic cancer patients. Scientific Reports, 2021, 11, 20797.	3.3	3
4	Early peritoneal metastasis after laparoscopic incisional hernia repair secondary to colon cancer resection: A case report. Annals of Medicine and Surgery, 2021, 71, 103000.	1.1	0
5	Tolerability and Adverse Events of Adjuvant Chemotherapy for Rectal Cancer in Patients With Diverting Ileostomy. In Vivo, 2020, 34, 3399-3406.	1.3	3
6	Clinical significance of monitoring KRAS in tissue and plasma of pancreatic cancer patients Journal of Clinical Oncology, 2020, 38, 745-745.	1.6	0
7	Multiple primary malignancies of six organs in a Japanese male patient: A case report. Molecular and Clinical Oncology, 2019, 10, 511-515.	1.0	4
8	Efficacy of Neoadjuvant Chemotherapy with Capecitabine plus Oxaliplatin in the Treatment of Locally Advanced Sigmoid Colon Cancer Invading the Urinary Bladder: A Report of Three Cases. Case Reports in Surgery, 2019, 2019, 1-7.	0.4	3
9	Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS ONE, 2019, 14, e0227366.	2.5	57
10	Clinical significance of monitoring KRAS in tissue and plasma of pancreatic cancer patients Journal of Clinical Oncology, 2019, 37, 254-254.	1.6	0
11	Significance of monitoring plasma vascular endothelial growth factor signals during treatment of colorectal cancer patients Journal of Clinical Oncology, 2019, 37, 577-577.	1.6	0
12	Satellite alpha transcript levels to predict risk of bilateral breast cancer and multiple primary cancer in patients with breast cancer who lack <i>BRCA</i> -related clinical features Journal of Clinical Oncology, 2019, 37, e12575-e12575.	1.6	0
13	Sequential assessments of <i><i>KRAS-</i></i> mutated circulating tumor DNA in longitudinal monitoring enable the prediction of prognosis and therapeutic responses in patients with pancreatic cancer Journal of Clinical Oncology, 2019, 37, e15712-e15712.	1.6	1
14	High relative levels of satellite alpha transcripts predict increased risk of bilateral breast cancer and multiple primary cancer in patients with breast cancer and lacking BRCA‑related clinical features. Oncology Reports, 2019, 42, 857-865.	2.6	4
15	Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report. Surgical Case Reports, 2019, 5, 145.	0.6	1
16	Title is missing!. , 2019, 14, e0227366.		0
17	Title is missing!. , 2019, 14, e0227366.		0

Коісні Suzuki

#	Article	IF	CITATIONS
19	Title is missing!. , 2019, 14, e0227366.		О
20	Methylation-Sensitive Amplification Length Polymorphism (MS-AFLP) Microarrays for Epigenetic Analysis of Human Genomes. Methods in Molecular Biology, 2018, 1766, 137-156.	0.9	3
21	A High Abdominal Aortic Calcification Score on CT is a Risk Factor for Postoperative Pancreatic Fistula in Elderly Patients Undergoing Pancreaticoduodenectomy. World Journal of Surgery, 2018, 42, 1129-1137.	1.6	16
22	Monitoring circulating tumor DNA revealed dynamic changes in <i>KRAS</i> status in patients with metastatic colorectal cancer. Oncotarget, 2018, 9, 24398-24413.	1.8	29
23	Surgical Resection with Neoadjuvant Chemotherapy for Locoregionally Recurrent Appendiceal Cancer Invading the External Iliac Vessels. Case Reports in Surgery, 2018, 2018, 1-6.	0.4	1
24	Overexpression of satellite alpha transcripts leads to chromosomal instability via segregation errors at specific chromosomes. International Journal of Oncology, 2018, 52, 1685-1693.	3.3	17
25	Monitoring circulating tumor DNA revealed dynamic changes in KRAS status in patients with metastatic colorectal cancer Journal of Clinical Oncology, 2018, 36, e15630-e15630.	1.6	1
26	Dynamics and characteristics of KRAS mutated circulating tumor DNA in patients with metastatic colorectal cancer during various treatments Journal of Clinical Oncology, 2018, 36, 665-665.	1.6	0
27	Clinical significance of monitoring KRAS in tissue and serum of pancreatic cancer patients Journal of Clinical Oncology, 2018, 36, 286-286.	1.6	0
28	Efficacy, tolerability, and manageability of TAS-102 plus bevacizumab for metastatic colorectal cancer patients in clinical practice Journal of Clinical Oncology, 2018, 36, e15535-e15535.	1.6	1
29	Significance of monitoring vascular endothelial growth factor signals in blood during treatment of colorectal cancer patients Journal of Clinical Oncology, 2018, 36, e15563-e15563.	1.6	0
30	The significance of monitoring KRAS, human epidermal growth factor receptor 2, and vascular endothelial growth factor signals in the blood of colorectal cancer patients during treatment Journal of Clinical Oncology, 2018, 36, e24053-e24053.	1.6	0
31	Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. Pathology and Oncology Research, 2017, 23, 737-744.	1.9	3
32	Clinical and molecular assessment of regorafenib monotherapy. Oncology Reports, 2017, 37, 2506-2512.	2.6	15
33	Morphological response contributes to patient selection for rescue liver resection in chemotherapy patients with initially un-resectable colorectal liver metastasis. Oncology Letters, 2017, 14, 1491-1499.	1.8	6
34	Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer. Oncology Letters, 2017, 13, 4947-4952.	1.8	4
35	Satellite alpha transcripts as a biomarker to predict the development of breast cancer with bilateral or multiple primary malignancies Journal of Clinical Oncology, 2017, 35, e23202-e23202.	1.6	1
36	Overexpression of satellite alpha transcript in breast cancer patients to impair specific chromosomes Journal of Clinical Oncology, 2017, 35, e23216-e23216.	1.6	1

Коісні Suzuki

#	Article	IF	CITATIONS
37	The clinical significance of KRAS monitoring in tumor tissues and blood of patients with pancreatic tumor Journal of Clinical Oncology, 2017, 35, 334-334.	1.6	1
38	En blocpancreaticoduodenectomy and right hemicolectomy for locally advanced right-sided colon cancer. World Journal of Gastrointestinal Oncology, 2017, 9, 372.	2.0	15
39	Clinical significance of monitoring <i>KRAS</i> in the blood of pancreatic cancer patients Journal of Clinical Oncology, 2017, 35, e23042-e23042.	1.6	0
40	Difference in appearance of KRAS mutated circulating tumor DNA in patients with metastatic colorectal cancer during treatments Journal of Clinical Oncology, 2017, 35, e23025-e23025.	1.6	0
41	Clinical significance of FDG-PET/CT in assessment of recurrence in breast cancer patients before surgery Journal of Clinical Oncology, 2017, 35, e23215-e23215.	1.6	0
42	Heterogeneous expression of zinc-finger E-box-binding homeobox 1 plays a pivotal role in metastasis via regulation of miR-200c in epithelial-mesenchymal transition. International Journal of Oncology, 2016, 49, 1057-1067.	3.3	13
43	Clinical characteristics of synchronous colorectal cancers in Japan. World Journal of Surgical Oncology, 2016, 14, 272.	1.9	24
44	Clinical and molecular assessment of response to regorafenib Journal of Clinical Oncology, 2016, 34, 568-568.	1.6	3
45	Liquid biopsy leads to a paradigm shift in cancer treatment Journal of Clinical Oncology, 2016, 34, 602-602.	1.6	1
46	Practical applications of "liquid biopsy―in the colorectal cancer treatment Journal of Clinical Oncology, 2016, 34, e23044-e23044.	1.6	0
47	Improving metachronous cancer risk assessment using clinicopathological information in colorectal cancer patients Journal of Clinical Oncology, 2016, 34, e15092-e15092.	1.6	0
48	Epigenetic inactivation of the extracellular matrix metallopeptidase ADAMTS19 gene and the metastatic spread in colorectal cancer. Clinical Epigenetics, 2015, 7, 124.	4.1	24
49	Multiple primary malignancies involving primary sporadic colorectal cancer in Japan: incidence of gastric cancer with colorectal cancer patients may be higher than previously recognized. World Journal of Surgical Oncology, 2015, 13, 23.	1.9	25
50	Detection of satellite alpha transcript in sera, as a surrogate marker for the risk of development of multiple cancers in colorectal cancer patients Journal of Clinical Oncology, 2015, 33, e22044-e22044.	1.6	1
51	Emergence of <i>KRAS</i> mutation in detection of circulating tumor DNA during treatments for metastatic gastrointestinal cancer patients Journal of Clinical Oncology, 2015, 33, 11026-11026.	1.6	0
52	XELIRI regimen plus continuous treatment with bevacizumab is well-tolerated and effective in metastatic colorectal cancer patients in a second-line setting involving the sequential administration of XELOX and XELIRI. Molecular and Clinical Oncology, 2014, 2, 827-832.	1.0	4
53	DNA methylation alterations of AXIN2 in serrated adenomas and colon carcinomas with microsatellite instability. BMC Cancer, 2014, 14, 466.	2.6	25
54	Multiple primary malignancies involving primary sporadic colorectal cancer in Japan: Incidence of gastric cancer with colorectal cancer patients may be higher than previously recognized Journal of Clinical Oncology, 2014, 32, 1583-1583.	1.6	0

Коісні Suzuki

#	Article	IF	CITATIONS
55	Array-based identification of common DNA methylation alterations in ulcerative colitis. International Journal of Oncology, 2012, 40, 983-994.	3.3	21
56	Sessile serrated adenoma shares similar genetic and epigenetic features with microsatellite unstable colon cancer in a location-dependent manner. Experimental and Therapeutic Medicine, 2011, 2, 695-700.	1.8	25
57	Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer. International Journal of Oncology, 2011, 40, 217-26.	3.3	11
58	Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell, 2006, 9, 199-207.	16.8	245
59	The genomic damage estimated by arbitrarily primed PCR DNA fingerprinting is useful for the prognosis of gastric cancer. Gastroenterology, 2003, 125, 1330-1340.	1.3	48